Improving Outcomes in OAB: New and Emerging Strategies to Reduce Symptom Burden and Treatment Adverse Effects (CME/CE Webcast)
Activity Description and Purpose
Overactive bladder (OAB) is a common condition that can significantly impair quality of life and carries a substantial personal and societal economic burden. Available evidence indicates that OAB is undertreated and inappropriately treated through the use of antimuscarinic medications in patients with dementia. Current and emerging β3-adrenoceptor agonist therapies may have a better risk:benefit profile. The desired results of this activity are for urologists and other clinicians to improve their diagnosis and treatment of OAB.
This educational activity is intended for urologists, urogynecologists, physician assistants, nurse practitioners, nurses, and other clinicians caring for patients with overactive bladder.
After completing this activity, participants will be better able to:
- Apply efficacy and tolerability clinical data to develop long-term treatment plans for patients with overactive bladder
- Incorporate medication reviews into patient encounters
- Compare the data on central nervous system effects of antimuscarinic overactive bladder medications with those of β3-adrenoceptor agonists
- Describe the pharmacologic, efficacy, safety, and tolerability profiles of new and emerging treatments for overactive bladder
|Roger Dmochowski, MD, MMHC, FACS (Chair)|
Associate Surgeon in Chief
Professor of Surgery
Professor of Urology
Professor of Obstetrics and Gynecology
Vice Chair, Section of Surgical Sciences
Vanderbilt University Medical Center
|Benjamin M. Brucker, MD|
Departments of Urology and Obstetrics and Gynecology
Director, Female Pelvic Medicine and Reconstructive Surgery Program and Neurourology
New York University Langone Health
New York, New York
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Benjamin M. Brucker, MD, is a consultant for Allergan, Click Therapeutics, Inc, and Urovant Sciences, Inc; is on the speakers bureau for Allergan; is a contracted researcher for Boston Scientific Corporation; and has ownership interest (future stock options) in Watkins-Conti Products, Inc.
Roger Dmochowski, MD, MMHC, is a medical monitor for BlueWind Medical, Caldera Medical, and Viveve.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Urovant Sciences, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Urovant Sciences, Inc.
©2020 MedEdicus LLC. 230.2
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Clicking Register indicates that you have reviewed the CME/CE information for this activity.
Learning Method and Medium
This educational activity consists of a five (5)-question pretest, a webcast, and five (5) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the posttest, and complete the evaluation. To receive credit for this activity, please complete the posttest and evaluation. This educational activity should take a maximum of 1.0 hour to complete.